Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
COMPLETE
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
1 other identifier
observational
3,000
1 country
68
Brief Summary
Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2010
Longer than P75 for all trials
68 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2010
CompletedFirst Submitted
Initial submission to the registry
April 23, 2010
CompletedFirst Posted
Study publicly available on registry
April 27, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2019
CompletedJanuary 13, 2020
January 1, 2020
9.8 years
April 23, 2010
January 8, 2020
Conditions
Keywords
Eligibility Criteria
Patients will be enrolled from academic and community cancer centers in the United States, France, Germany, Italy and Japan.
You may qualify if:
- Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL):
- Aggressive natural killer (NK)-cell leukemia
- Adult T-cell lymphoma/leukemia (human T-cell leukemia virus \[HTLV\] 1+)
- Angioimmunoblastic T-cell lymphoma
- Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)
- PTCL, not otherwise specified (NOS)
- T/NK-cell lymphoma, nasal type
- Enteropathy-type intestinal lymphoma
- Hepatosplenic T-cell lymphoma
- Subcutaneous panniculitis T-cell lymphoma
- Transformed mycosis fungoides (at diagnosis of transformation)
- T-cell prolymphocytic leukemia (T-PLL)
- Cutaneous gamma/delta (γ/δ) T-cell lymphoma
- Cutaneous aggressive CD8+ T-cell lymphoma
- Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm)
- +1 more criteria
You may not qualify if:
- Patient gives written informed consent
- Patient has other T- or NK-cell malignancies including:
- Precursor T/NK neoplasms
- T-cell large granular lymphocytic leukemia
- Mycosis fungoides, other than transformed mycosis fungoides
- Sézary syndrome
- Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (68)
DCH Cancer Treatment Center
Tuscaloosa, Alabama, 35401, United States
Arizona Cancer Center
Tucson, Arizona, 85724, United States
Genesis Cancer Center
Hot Springs, Arkansas, 71913, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
City of Hope National Medical Center
Duarte, California, 91010, United States
Moores Cancer Center UCSD
La Jolla, California, 92037, United States
Wilshire Oncology Medical Group
La Verne, California, 91750, United States
UCLA
Los Angeles, California, 90025, United States
USC & Norris Cancer Center
Los Angeles, California, 90033, United States
Stanford University Medical Center
Stanford, California, 94305, United States
UCLA Olive View Medical Center
Sylmar, California, 91342, United States
Danbury Hospital Praxair Cancer Center
Danbury, Connecticut, 06810, United States
Yale University School of Medicine
New Haven, Connecticut, 06510, United States
Washington Cancer Institute at Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
Georgetown University
Washington D.C., District of Columbia, 20057, United States
Coral Springs Oncology
Coral Springs, Florida, 33065, United States
Medical Specialists of the Palm Beaches
Lake Worth, Florida, 33463, United States
Hematology Oncology Associates
Loxahatchee Groves, Florida, 33463, United States
University of Miami
Miami, Florida, 33146, United States
MD Anderson Orlando
Orlando, Florida, 32806, United States
Moffit Cancer Center
Tampa, Florida, 32806, United States
Emory University Cancer Center
Atlanta, Georgia, 30322, United States
Georgia Cancer Specialists
Atlanta, Georgia, 30341, United States
Medical College of Georgia
Augusta, Georgia, 30912, United States
Kootenai Cancer Center
Post Falls, Idaho, 83854, United States
Northwestern University
Chicago, Illinois, 60208, United States
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois, 60612, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
UIC Cancer Center
Chicago, Illinois, 60612, United States
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
Simmons Cooper Cancer Institute at SIU School of Medicine
Springfield, Illinois, 62702, United States
Indiana University Simon Cancer Center
Indianapolis, Indiana, 46202, United States
St. Francis Medical Group Oncology and Hematology Associates
Indianapolis, Indiana, 46237, United States
Louisiana State University Health Science Center (LSUHSC)
Shreveport, Louisiana, 70112, United States
University of Maryland
Baltimore, Maryland, 20742, United States
Boston Medical Center
Boston, Massachusetts, 02118, United States
Michigan State University
East Lansing, Michigan, 48824, United States
Genesys Hurley Cancer Institute
Flint, Michigan, 48503, United States
West Michigan Cancer Center
Kalamazoo, Michigan, 49007, United States
ProMedica
Lambertville, Michigan, 48144, United States
Metro Minnesota Community Clinical Oncology Program
Saint Louis Park, Minnesota, 55426, United States
Research Medical Center
Kansas City, Missouri, 64132, United States
St. Louis University Cancer Center
St Louis, Missouri, 63110, United States
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03766, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
Overlook Hospital and Morristown Memorial Hospital
Summit, New Jersey, 07960, United States
Roswell Park Cancer Institute
Buffalo, New York, 14203, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
New York University Clinical Cancer Center
New York, New York, 10065, United States
University of Rochester
Rochester, New York, 14642, United States
University of North Carolina Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Carolinas Medical Center Northeast
Concord, North Carolina, 28025, United States
Carolina Cancer Management, Inc.
Fayetteville, North Carolina, 28304, United States
Community Cancer Center
Lorain, Ohio, 44035, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
Guthrie Clinic, Ltd
Sayre, Pennsylvania, 18840, United States
University of Tennessee Cancer Institute
Memphis, Tennessee, 37920, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
UT Southwestern
Dallas, Texas, 75390, United States
Center for Cancer and Blood Disorders
Fort Worth, Texas, 76104, United States
JPS Center for Cancer Care
Fort Worth, Texas, 76104, United States
South Texas Oncology and Hematology, P.A.
San Antonio, Texas, 76104, United States
Tyler Hematology Oncology, PA
Tyler, Texas, 75766, United States
University of Virginia Health System
Charlottesville, Virginia, 22903, United States
West Virginia University
Morgantown, West Virginia, 26506, United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53705, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Francine Foss, MD
Yale University
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 23, 2010
First Posted
April 27, 2010
Study Start
February 1, 2010
Primary Completion
December 1, 2019
Study Completion
December 1, 2019
Last Updated
January 13, 2020
Record last verified: 2020-01